For prescribing information, click here

This website has been commissioned by Ipsen Pharmaceuticals Ltd. and is intended for an Irish audience. If you are not a Healthcare Professional, please click here.
Adverse event reporting information is available at the bottom of this webpage.

This website has been commissioned by Ipsen Pharmaceuticals Ltd. and is intended for an Irish audience

Resources

Prostate Cancer

Decapeptyl® (triptorelin) SR 3 mg, Decapeptyl® (triptorelin) 3-month 11.25 mg and Decapeptyl® (triptorelin) 6-month 22.5 mg therapeutic indications.

Decapeptyl® (triptorelin) SR and Decapeptyl® (triptorelin) 3-month are indicated for:

  • Management of advanced prostatic carcinoma.

Decapeptyl® (triptorelin) 6-month is indicated for:

  • Treatment of locally advanced or metastatic.
  • Hormone-dependent prostate cancer.

Information About Decapeptyl®

Why Decapeptyl<sup>®</sup> (triptorelin)
Why Decapeptyl® (triptorelin)

Know more why you should choose Decapeptyl® (triptorelin) for prostate cancer treatment.

TRI-IE-000615 | September 2025
Practical Prescribing
Practical Prescribing

Explore this page to learn more about Decapeptyl® (triptorelin) approved indications, mechanism of action, dosing and administration. This webpage is designed to be viewed on a laptop screen or larger.

TRI-IE-000616 | October 2025

Efficacy & Tolerability

Decapeptyl<sup>®</sup> (triptorelin) Clinical Data
Decapeptyl® (triptorelin) Clinical Data

Explore this page to learn more about Decapeptyl® (triptorelin) key clinical data, efficacy and well established safety profile.

TRI-IE-000617 | October 2025

Support for Your Patients

Decapeptyl<sup>®</sup> (triptorelin) and your treatment journey guide
Decapeptyl® (triptorelin) and your treatment journey guide
PDF / PowerPoint Deck 12 pages

This guide is intended only for men prescribed LHRHa treatment for prostate cancer with Decapeptyl® (triptorelin). It is designed to help men understand their prostate cancer treatment and how to get the most from it.

TRI-IE-000608 | August 2025

Contact your Ipsen representative

Send request
Resources

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.

To access relevant information about Prostate Cancer, please choose one of the following options:

I am a healthcare professional in Ireland

This section is for healthcare professionals only. Contains promotional information

I am a healthcare professional in Ireland

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.

I am a patient

This section provides information to support patients that have been prescribed Decapeptyl® (triptorelin) in Ireland. It is designed for patients in Ireland and should not replace the opinion provided by your healthcare professional or the details contained in the Patient Information Leaflet.

I am a patient

I am a member of the general public

This section is for members of the general public.

I am a member of the general public

Reporting of side effects:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly to the HPRA. Reporting forms and information can be found at www.hpra.ie or email medsafety@hpra.ie. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256. By reporting side effects, you can help provide more information on the safety of this medicine.